Flat sales at Guerbet in first nine months:
This article was originally published in Clinica
Sales at French contrast agent manufacturer Guerbet were flat at Fr 792 million ($158 million) in the first nine months of 1996. Net profits, however, were down 17% from Fr 40 million in 1995 to Fr 33 million this year. President Michel Guerbet blames cost control measures in France and a general reduction in prices. Xenetix, the company's non-ionic X-ray agent, recorded the strongest growth over the period, with sales up 400% compared with 1995. Xenetix now represents 11% of Guerbet's turnover. International sales increased 6% in the first nine months.
You may also be interested in...
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.